Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445136 | 1.00 | MEN1 (0.64) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL1643494 | 0.87 | MEN1 (0.63) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL5824225 | 0.87 | MEN1 (0.63) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL16915066 | 0.86 | MEN1 (0.61) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL21877806 | 0.85 | LMNA (0.60) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL21647333 | 0.85 | LMNA (0.60) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL21877811 | 0.85 | LMNA (0.60) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL234697 | 0.85 | MEN1 (0.69) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL677165 | 0.85 | MEN1 (0.69) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL2565442 | 0.85 | MEN1 (0.69) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226401-A1 | TECHNIQUES FOR PREDICTING DIALYSIS ACCESS SITE OUTCOMES | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250003930-A1 | METHOD FOR ANALYZING AMINO ACIDS AND/OR ACYLCARNITINES | SHIMADZU CORPORATION (JP) | 2025-01-02 | — | — | US | claimed |
| CN-119224197-A | Method for analyzing amino acid and/or acyl carnitine | 株式会社岛津制作所 | 2024-12-31 | — | — | CN | claimed |
| CN-118731196-A | Qualitative and quantitative detection and analysis method and system for acyl carnitine and compound thereof | 复旦大学 | 2024-10-01 | — | — | CN | claimed |
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-18 | — | — | US | claimed |
| EP-3908374-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2021-11-17 | — | — | EP | claimed |
| US-20210330734-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. | 2021-10-28 | — | — | US | claimed |
| WO-2021211540-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-21 | — | — | WO | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | claimed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | claimed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | claimed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-0376899-B1 | USE OF L-CARNITINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE THERAPEUTICAL TREATMENT OF PERIPHERAL NEUROPATHIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1993-08-04 | — | — | EP | claimed |
| US-5227518-A | L-CARNITINE DERIVATIVES AS THERAPEUTICAL AGENTS FOR TREATING MYOPATHIES AND NEURONAL DEGENERATION AND FOR INHIBITING PROTEOLYSIS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-07-13 | — | — | US | claimed |
| EP-0516594-A1 | L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-12-02 | — | — | EP | claimed |
| US-5043355-A | Use of L-carnitine derivatives in the therapeutical treatment of peripheral neuropathies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1991-08-27 | — | — | US | claimed |
| EP-0376899-A2 | Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1990-07-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | CRAT, OPRK1, OPRD1 | MEN1 4830/4885KMT2A 176/4885CYP2C19 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.